PharmaSGP Holding SE Logo

PharmaSGP Holding SE

Develops and markets leading natural OTC drugs for chronic conditions in the European market.

PSG | F

Overview

Corporate Details

ISIN(s):
DE000A2P4LJ5
LEI:
3912005CZ12PVVCIPT91
Country:
Germany
Address:
Lochhamer Schlag 1, 82166 Gräfelfing

Description

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of leading over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive remedies based on natural pharmaceutical active ingredients with documented efficacy and minimal known side effects. Its core brands are market leaders in Germany and other European countries for chronic indications, including rheumatic and nerve pain (RubaXX®, Restaxil®), sleep disorders (Baldriparan®), and sexual weakness (DESEO®, NERADIN®). Since launching its first product in 2012, PharmaSGP has expanded its business model across Europe. The company's growth is driven by organic brand development and strategic acquisitions, such as its 2021 purchase of an OTC brand portfolio from GSK.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-28 17:50
FUTRUE increases adequate cash compensation under the squeeze-out
English 8.2 KB
2025-09-22 15:15
PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out
English 7.3 KB
2025-09-19 14:15 English 3.9 KB
2025-09-11 09:00
PharmaSGP publishes preliminary half-year figures for 2025
English 15.7 KB
2025-08-14 12:00
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,315 additional shares…
English 6.8 KB
2025-08-11 13:00
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 39,678 additional share…
English 6.8 KB
2025-08-08 11:47
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 873 additional shares o…
English 6.8 KB
2025-08-07 13:11
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,505 additional shares…
English 6.8 KB
2025-08-06 16:16
PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchan…
English 7.8 KB
2025-08-05 10:48
PharmaSGP Holding SE: Michael Rudolf, Tender of 4,169 shares within the public …
English 5.9 KB
2025-08-04 13:58
PharmaSGP Holding SE: Dr. Clemens Fischer, Tender of a total of 6,062 addition…
English 6.6 KB
2025-07-28 17:04
PharmaSGP Holding SE publishes joint reasoned statement of the Management Board…
English 9.2 KB
2025-07-28 14:11
PharmaSGP Holding SE: FUTRUE GmbH, Tender of an additional total of 4,491 share…
English 6.9 KB
2025-07-24 15:30
PharmaSGP Holding SE: FUTRUE GmbH, buy
English 6.0 KB
2025-07-24 14:11
FUTRUE GmbH submits request to implement squeeze-out of minority shareholders o…
English 8.2 KB

Automate Your Workflow. Get a real-time feed of all PharmaSGP Holding SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmaSGP Holding SE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmaSGP Holding SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-10-13 Zeitfracht GmbH & Co. KGaA Close relation Sell None 61,610.00 EUR
2021-10-13 Müller, Dr. Axel Supervisory board Other None 4,714.50 EUR
2021-10-12 FUTRUE GmbH Close relation Buy None 1,743,861.20 EUR
2021-10-12 Zeitfracht GmbH & Co. KGaA Close relation Sell None 64,640.00 EUR
2021-10-05 Horch, Johann Board Buy None 7,519.48 EUR
2021-07-07 FUTRUE GmbH Close relation Buy None 6,789,825.00 EUR
2021-07-07 MVH Beteiligungs- und Beratungs-GmbH Close relation Buy None 754,425.00 EUR
2021-07-01 Sultzer, Marcus Board Other None 499,966.00 EUR
2021-07-01 Weick, Achim Board Other None 76,000.00 EUR
2021-07-01 Vogel, Rony Supervisory board Other None 114,000.00 EUR

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.